Drug major Cipla Ltd announced on Thursday that its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to the cancer drug Keytruda in the United States.
Partnership Details
The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to advanced therapies for cancer patients while lowering treatment costs, Cipla stated in a regulatory filing. Under the agreement, Qilu will be responsible for the development, regulatory registration, and supply of the product, while Cipla will leverage its commercial presence to market the asset in the US.
Statements from Leadership
"This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio," said Achin Gupta, Managing Director and Global Chief Executive Officer of Cipla.
